- Home
- PLUG vs ETNB Comparison
PLUG vs ETNB Comparison
Compare PLUG & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUG
- ETNB
- Stock Information
- Founded
- PLUG 1997
- ETNB 2018
- Country
- PLUG United States
- ETNB United States
- Employees
- PLUG N/A
- ETNB N/A
- Industry
- PLUG Industrial Machinery/Components
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- PLUG Energy
- ETNB Health Care
- Exchange
- PLUG Nasdaq
- ETNB Nasdaq
- Market Cap
- PLUG 1.0B
- ETNB 1.0B
- IPO Year
- PLUG 1999
- ETNB 2019
- Fundamental
- Price
- PLUG $0.88
- ETNB $10.10
- Analyst Decision
- PLUG Hold
- ETNB Strong Buy
- Analyst Count
- PLUG 16
- ETNB 8
- Target Price
- PLUG $1.76
- ETNB $26.43
- AVG Volume (30 Days)
- PLUG 158.5M
- ETNB 2.1M
- Earning Date
- PLUG 05-12-2025
- ETNB 05-01-2025
- Dividend Yield
- PLUG N/A
- ETNB N/A
- EPS Growth
- PLUG N/A
- ETNB N/A
- EPS
- PLUG N/A
- ETNB N/A
- Revenue
- PLUG $642,224,000.00
- ETNB N/A
- Revenue This Year
- PLUG $23.88
- ETNB N/A
- Revenue Next Year
- PLUG $25.84
- ETNB N/A
- P/E Ratio
- PLUG N/A
- ETNB N/A
- Revenue Growth
- PLUG N/A
- ETNB N/A
- 52 Week Low
- PLUG $0.69
- ETNB $4.16
- 52 Week High
- PLUG $3.55
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- PLUG 49.62
- ETNB 61.20
- Support Level
- PLUG $0.74
- ETNB $8.94
- Resistance Level
- PLUG $1.03
- ETNB $9.89
- Average True Range (ATR)
- PLUG 0.08
- ETNB 0.68
- MACD
- PLUG 0.03
- ETNB 0.11
- Stochastic Oscillator
- PLUG 56.68
- ETNB 71.75
About PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).